Solu-Medrol®

Unique, Ready-to-Mix Device for Bedside Use

Pfizer is the only manufacturer to provide Solu-Medrol (methylprednisolone sodium succinate) in the unique Act-O-Vial system. The Act-O-Vial is a one-piece design, with two chambers: one that holds sterile water for injection or benzyl alcohol and water for injection, and one that holds the lyophilized drug.6 By pressing down on the device, both chambers combine, allowing for self-contained mixing and use of the product.6

This unique dual-chamber system6:

  • Reduces steps needed for medication preparation compared to traditional vial methods
  • Is designed for easy mixing and complete reconstitution
  • Can be stored in automated dispensing machines (ADMs)
  • Supports urgent patient care needs with premeasured doses
  • Is available in a wide range of strengths
  • Doesn’t require freezing, thawing, or refrigeration
Dating:

Available in multiple strengths. Shelf-life up to 4 years depending on strength5

Features:

Select strengths are gluten free, preservative free,* and/or do not use natural rubber latex in the manufacturing of the device or drug container closure system.
View Features

Indications

When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows:

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.

Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.

To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.

Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia.

Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.

For the palliative management of leukemias and lymphomas.

Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.

Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.

To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.

Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

REFERENCES
1. Growth Dynamics Audit from September 2013 to September 2017. NSP Audit from October 2011 to September 2017. IMS Health. 2017
2. Methylprednisolone 2012-2017. IMS Health. 2017
3. National Library of Medicine. Daily Med: Current Clinical Information. SOLU-MEDROL label. Pharmacia and Upjohn Company. https://dailymed.nlm.nih.gov/dailymed/ getFile.cfm?setid=cd99be87-c8d9-48d6-a8e5-e081052e3f19&type=pdf&name=cd99be87-c8d9-48d6-a8e5-e081052e3f19. Accessed November 27, 2017.
4. National Library of Medicine. Daily Med: Current Clinical Information. DEPO-MEDROL label. Pharmacia and Upjohn Company. https://dailymed.nlm.nih.gov/dailymed/ getFile.cfm?setid=9a7b3837-e038-48bf-97e9-78ad463760dc&type=pdf&name=9a7b3837-e038-48bf-97e9-78ad463760dc. Accessed November 27, 2017.
5. Data on File. Pfizer Inc, New York, NY.
6. USPI Solu-Medrol®. New York, NY: Pfizer, Inc. 2018
7. USPI Depo-Medrol®. New York, NY: Pfizer, Inc. 2018